Related Experiment Video
Updated: Jun 1, 2026

08:05
Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
p21-activated kinase 1: PAK'ed with potential
Christy C Ong1, Adrian M Jubb, Wei Zhou
1Department of Translational Oncology, Genentech, Inc., South San Francisco, CA 94080, USA.
Oncotarget
|June 10, 2011
Summary
P21-activated kinases (PAKs) are key in cell growth and tumor development. Inhibiting PAK1 shows promise for arresting tumor growth and promoting cancer cell death.
Area of Science:
- Cell Biology
- Molecular Oncology
- Biochemistry
Background:
- P21-activated kinases (PAKs) are crucial regulators of cell signaling pathways involved in proliferation, cell polarity, invasion, and actin cytoskeleton organization.
- Dysregulation of PAKs, particularly PAK1, is implicated in various aspects of tumorigenesis.
- Targeting PAK activity presents a potential therapeutic strategy for cancer treatment.
Purpose of the Study:
- To review the role of PAK1 in growth factor signaling and its contribution to cancer development.
- To explore the mechanisms by which PAK1 inhibition can lead to tumor growth arrest and apoptosis.
- To identify specific cancer types where PAK1 inhibition may be a promising therapeutic approach.
Main Methods:
- Literature review and synthesis of recent research data.
- Analysis of signaling pathways involving PAK1 in cancer.
- Discussion of potential therapeutic strategies targeting PAK1.
Main Results:
- PAK1 is a significant mediator of growth factor signaling pathways that drive cancer progression.
- Inhibition of PAK1 can effectively halt tumor growth by disrupting critical cellular processes.
- PAK1 inhibition promotes apoptosis, leading to cancer cell death.
Conclusions:
- PAK1 plays a critical role in tumorigenesis and represents a viable therapeutic target.
- Targeting PAK1 offers a promising strategy for developing novel anti-cancer treatments.
- Further research into PAK1 inhibition in specific cancer types is warranted.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

